Sigrid Therapeutics Advances Diabetes Management with SiPore® Food
Innovative Access to SiPore® Technology
Sigrid Therapeutics is thrilled to share that it has successfully secured U.S. market access for its groundbreaking SiPore® technology following the impressive results from the SHINE study, which is recognized as the largest study of its kind in prediabetes.
About the SHINE Study
The SHINE study provided pivotal insights into the efficacy of Carb Fence™, an innovative medical-grade liquid formula that utilizes SiPore®. This formula has shown to effectively lower long-term blood sugar levels, as measured by HbA1c, enhance glucose metabolism, and assist in body weight reduction while maintaining muscle mass. Such robust findings highlight Carb Fence™ as a pioneering product in the U.S. market for medical food, a category strictly regulated by the FDA.
U.S. Medical Food Market Growth
Carb Fence™ is particularly noteworthy as it is the first clinically validated medical food tailored specifically for individuals facing prediabetes, a condition that currently affects around one-third of adults in the U.S. This product's market entry aims to address the increasing prevalence of prediabetes and diabetes within the population.
Voices from Leadership
In a recent statement, Sana Alajmovic, Co-Founder and CEO of Sigrid Therapeutics, emphasized, "These achievements endorse SiPore® as a viable, effective, and reachably solution to combat the escalating diabetes and obesity crises, while paving the way for further expansion into diverse sectors."
Significant Study Results
The SHINE study was designed as a double-blind, placebo-controlled, randomized trial, assessing both the safety and efficacy of the SiPore®-enhanced Carb Fence™. This extensive trial included 318 participants with elevated blood sugar and excess weight, conducted across 27 clinics in three different European nations.
Understanding the Impact on Participants
Results indicated that both male and female participants experienced significant reductions in A1C levels from baseline. Notably, women showcased a clinically relevant and statistically significant improvement compared to the placebo group. Although men also demonstrated meaningful reductions, statistical significance was not fully achieved due to a higher-than-expected placebo effect, which is often observed in clinical trials.
Interestingly, some male participants in the placebo group also showed notable improvements in liver health, likely stemming from lifestyle changes despite receiving instructions to maintain their usual habits. Removing participants with significant liver improvements from the analysis resulted in the elimination of the placebo effect on A1C, highlighting the importance of externally influenced behaviors in clinical outcomes.
Contact Information
For more inquiries about Sigrid Therapeutics, please reach out to Sana Alajmovic, Co-Founder and CEO, who is readily available to address any questions or provide additional insights into the company and its initiatives.
Frequently Asked Questions
What is SiPore® technology?
SiPore® technology is a proprietary method developed by Sigrid Therapeutics, designed to enhance glucose metabolism and manage blood sugar levels through a unique medical food.
What is Carb Fence™?
Carb Fence™ is a fast-acting liquid formula that utilizes SiPore® technology, designed specifically for dietary management of prediabetes and helping to lower blood sugar levels.
What were the primary findings of the SHINE study?
The SHINE study found that Carb Fence™ significantly reduced A1C levels in participants and demonstrated improvements in glucose metabolism and weight management.
Who can benefit from Carb Fence™?
Individuals diagnosed with prediabetes, which affects approximately one in three adults in the U.S., can benefit from Carb Fence™ as part of their dietary management plan.
How can I learn more about Sigrid Therapeutics?
To gain more insights or for further information regarding Sigrid Therapeutics and their products, prospective users and partners are encouraged to reach out directly via the provided contact channels.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.